Table II. Clinical studies on modifications of hemostasis markers. DB, double-blind; PC, placebo-controlled; POC, prospective open comparative study; PO, prospective open; CS,cross-sectional; DEP, depression; SS, statistically significant; MAB, monoclonal antibodies; NA, non-available; IHD, ischemic heart disease; βTG, β-thromboglobulin; PF4, platelet factor 4; ANOVA, analysis of variance; PECAM, platelet endothelial cell adhesion molecule; 5-HT, serotonin; CI, confidence interval; PIT, platelet inositol triphosphate; LIBS, ligand-induced platelet binding site; aPTT, partial thromblastin time; INR, international normalized ratio; TT, thrombin time; AA, arachidonic acid; ADP, adenosine diphosphate; PT, prothtrombin time .

	Type of study	Subjects	N°	Treatment	SS modifications of hemostasis markers
Pollock et al, 200037	Randomized, DB	DEP + IHD	17	Paroxetine or	Paroxetine: ↓ βTG (P<0.01), PF4 (P<0.001);
				nortriptyline (6 weeks)	Nortriptyline: non-SS: ↓ PF4
Serebruany et al, 200336	Randomized,	Post-MI DEP	28	Sertraline (16 weeks)	↓ βTG (P=0.03), P-selectin (P=0.04),
	DB, PC				DB, PC E-selectin and βTG (ANOVA);
					non-SS: ↓ PF4, PECAM-I
Schins et al, 20048	Randomized,	Post-MI DEP	25/21	Mirtazapine (8 weeks)	Non-SS: ↓ βTG, PF4, platelet 5-HT
	DB, PC	vs non-DEP
Hergovich et al, 200035	Randomized,	Healthy	16	Paroxetine (2 weeks)	↓ platelet 5-HT by 83% (CI95: 74-92),
	DB, PC, CS/PO.				↓ collagen/epinephrine induced platelet
					aggregation by 31% (CI95: 6-56), 1CD63 by 8%
					(CI95:4-12)
Alvarez et al, 19999	POC	DEP vs	27/NA	Fluoxetine or	Fluoxetine: ↓ 5-HT plasma to 19% and
		healthy		clomipramine	platelet to 23%, ↓ of PIT (P<0.02);
				platelet to 23%, ↓ of PIT (P<0.02);	↓ platelet paroxetine receptor (P=0.03)
					Clomipramine: ↓ 5-HT plasma to 8% and platelet
					to 40%, ↓ of PIT (P<0.0001); ↓ platelet paroxetine
					receptor (P=0.05)
Markovitz et al, 200024	POC	DEP vs	17/21	Sertraline (6 weeks)	↓ collagen-induced platelet sécrétion
		healthy			by 19.5% (P<0.05)
Musselman et al, 200024	POC	DEP vs	15/12	Paroxetine (6 weeks)	↓ PF4 by 54%, platelet binding MAB
		healthy			anti-LIBS by 48% (P=0.0007) and GA6 by 17%
					(P=0.02) (ie, ↓ activation)
Gomez-Gil et al, 200430	POC	DEP vs	15/15	Imipramine (145 days)	↓ 5-HT induced platelet aggregation
		healthy			(P=0.038)
Piletz et al, 200016	POC	DEP vs healthy	19/17	Bupropion (6-8 weeks)	No SS changes in P-selectin levels
Menys et al, 199626	CS, POC	DEP vs	33/13	Fluoxetine or amitriptyline	Fluoxetine: ↓ plasma 5-HT (P<0.005),
		non-treated			↓ 5-HT induced aggregation; amitriptyline:
					no SS changes (P<0.05)
Laine-Cessac et al, 199827	PO	DEP	Fluoxetine	↓ epinephrine-induced platelet aggregation (P<0.025)
Alderman et al, 199628	PO	DEP	8	Fluoxetine or	No SS changes of platelet aggregation, aPTT,
				paroxetine (28 days)	PT, INR, platelet count
Tharmopathy et al, 200029	POC	DEP	7	Venlafaxine vs tricyclic Spontaneous platelet aggregation,	↓ P-Selectin
Lederbogen étal, 200131,32	POC	Dep	49	Amitriptyline or	Amitriptyline: ↓ prothrombin ratio
			paroxetine (5 weeks)		(100.9%, P0.002); non-SS: ↓ platelet
					aggregation
					Paroxetine: ↓ prothrombin ratio (99.1%, P<0.002);
					non-SS: ↓ platelet aggregation
Bang et al, 199133	Prosp. op.	Healthy	10	Fluoxetine (4-6 weeks)	No SS changes in platelet aggregation
					and coagulation factors
Berk et al, 199534	Prosp. op.	Dep	10	Fluoxetine	No SS changes in INR, aPTT, TT, bleeding time,
					factors II, V, VII, VIII:C, IX, X, XI, XII, fibrinogen,
					platelet sensitivity to AA, collagen, ADP, epinephrine
Serebruany et al, 200139	In vitro	IHD vs healthy	6/7	Sertraline	↓ platelet ADP-collagen-thrombin induced
					aggregability, ↓ P-selectin, CD9, PECAM-I,
					glycoprotein llb/llla and Ib
Mohammad et al, 197438	In vitro	Healthy	NA	Imipramine or amitriptyline	↓ ADP-induced platelet aggregation
Bondurant et al, 199840	In vitro	Healthy	5	Fluoxetine	No SS changes in PT